Cargando…
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
BACKGROUND AND AIMS: When the world was frantically searching for a drug effective against the coronavirus disease (COVID)-19, remdesivir, a broad-spectrum anti-viral medication, became a part of the COVID treatment. We planned a study to evaluate improvement in clinical outcomes with remdesivir tre...
Autores principales: | Mahajan, Lakshmi, Singh, A P, Gifty |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993042/ https://www.ncbi.nlm.nih.gov/pubmed/33814589 http://dx.doi.org/10.4103/ija.IJA_149_21 |
Ejemplares similares
-
Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022) -
Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021) -
Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis
por: Mastroianni, Antonio, et al.
Publicado: (2023) -
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score
por: Sellers, Jacob, et al.
Publicado: (2023) -
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
por: Tamura, Ryo, et al.
Publicado: (2023)